111Inlabeled

111In is a radioactive isotope of indium, with the chemical symbol 111In. It is produced by the neutron capture of stable indium-113, which is the most abundant isotope of indium. The nuclear reaction is typically induced in a nuclear reactor. 111In has a half-life of 2.84 days and decays primarily by electron capture to 111Sn, with a minor beta decay branch to 111Cd. It is used in various applications, particularly in the field of nuclear medicine.

In nuclear medicine, 111In is often used to label monoclonal antibodies and other biomolecules for imaging and therapeutic purposes. The isotope emits gamma rays with an energy of 171 keV and 245 keV, which are useful for imaging techniques such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET). The labeling process involves attaching the 111In to the biomolecule, allowing it to target specific tissues or tumors in the body.

The use of 111In-labeled compounds has been particularly significant in the treatment of certain types of cancer. For example, 111In-labeled octreotide (111In-DTPA-octreotide) is used to treat neuroendocrine tumors, such as carcinoid tumors and certain types of brain tumors. The labeled compound accumulates in the tumor tissue, delivering radiation directly to the cancer cells.

However, the use of 111In and other radioactive isotopes in medical applications must be carefully regulated to ensure safety and minimize radiation exposure to patients and healthcare workers. Proper shielding, handling procedures, and waste management are essential to manage the risks associated with radioactive materials.